6489 LOGO20THELANSIS 31

The overall average annual age-adjusted prevalence rate rose from 8.7 to 13.9 per 100,000 persons between the beginning and end of the surveillance period. The number of cases and case rate in the 50 to 80+ year age group was higher than in the 0–49-year age group. The age group that had the lowest average case rate was the 0–39-year age group, at 3 to 6 cases per 100,000 population. The pulmonary region (59%) was the most frequently reported site of disease followed by skin or soft tissue, bone or joints, and other parts of the body

Read more:- Non-Tuberculous Mycobacterial (NTM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Non-Tuberculous-Mycobacterial-NTM-forecast

 

Comprehensive insight on patient segmentation based on Age, Sex, types, growth rates and pigment production (Group I, II, III, IV), respiratory co-morbidities (Asthma, COPD, Bronchiectasis, TB, ABPA, HIV), specie (Mycobacterium kansasii, M marinum, Mycobacterium gordonae, M scrofulaceum; Mycobacterium aviumintracellulare (MAI) and M ulcerans; and Mycobacterium fortuitum, M chelonae, M abscessus, site-specific infection (Pulmonary region, Skin or soft tissue, bone or joint, Disseminated, Eye) has been provided into the epidemiology (Incidence and Prevalence) section of the Non-Tuberculous Mycobacterial (NTM) Infection and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

 

CI IMAGE

 

In terms of pharmacologic therapies, Several drug candidates are in Phase II and II/ III stages of development by various companies. Key assets among these are, nitric oxide; Novoteris, RHB-204; RedHillBiopharma, molgramostim; Savara, Vcc-486; Vertex Pharmaceuticals. Among these key assets, some of the assets are being designated as orphan drugs and fast track. The launch of key assets will positively impact the overall market from 2018 to 2030 in 8 MM countries. Apart from the above assets companies like Hsiri Therapeutics; antimycobacterial therapy, Qrumpharma; clofazimine, Revimmune; interleukin-7, SciBac; Mybacguard, Collaborations Pharmaceuticals; Mycobacterium Absceuusus infection therapy, Qrumpharma; QRM-008 are having their assets in the early phase of development.

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Bacterial vaginosis (BV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Atrioventricular septal defect (AVSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Cerebral palsy (CP) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Cholesteryl ester storage disease (CESD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Choroideremia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Non-Tuberculous Mycobacterial (NTM) market outlook report, Non-Tuberculous Mycobacterial (NTM) competitive landscape, Non-Tuberculous Mycobacterial (NTM) market forecast, Non-Tuberculous Mycobacterial (NTM)